Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Summary

Iron deficiency is prevalent in heart transplant recipients, and may be associated with reduced functional capacity. The IronIC trial is designed to assess the effect of intravenous iron isomaltoside on exercise capacity, muscle strength, cognition and quality of life in iron-deficient heart transplant recipients

Timeline

Start

2018-04-25

Primary completion

2020-02-27

Completion

2020-02-27

Publications

• Background Brautaset Englund KV, Ostby CM, Rolid K, Gude E, Andreassen AK, Gullestad L, Broch K. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. J Heart Lung Transplant. 2021 May;40(5):359-367. doi: 10.1016/j.healun.2021.01.1390. Epub 2021 Jan 23.
• Burker BS, Brautaset Englund KV, Myrdal Ostby C, Andersson S, Gullestad L, Broch K. Cognitive Function Among Heart Transplant Recipients Before and After Intravenous Iron Supplement for Iron Deficiency: Results From a Randomized, Placebo-Controlled, Double-Blind Treatment Trial. Clin Transplant. 2025 Nov;39(11):e70370. doi: 10.1111/ctr.70370.

Drugs

Indications

No indication recorded.